Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) – SVB Leerink lifted their FY2025 earnings estimates for Jazz Pharmaceuticals in a research note issued on Monday, January 23rd. SVB Leerink analyst M. Goodman now expects that the specialty pharmaceutical company will earn $18.94 per share for the year, up from their previous forecast of $18.59. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $15.17 per share. SVB Leerink also issued estimates for Jazz Pharmaceuticals’ FY2026 earnings at $20.19 EPS.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $4.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.35 by $0.18. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive return on equity of 30.71%. The company had revenue of $940.65 million for the quarter, compared to analyst estimates of $939.88 million.
Jazz Pharmaceuticals Price Performance
JAZZ stock opened at $153.15 on Tuesday. The company has a market capitalization of $9.64 billion, a P/E ratio of -510.50, a PEG ratio of 0.91 and a beta of 0.74. The company has a fifty day moving average price of $154.72 and a 200-day moving average price of $149.93. The company has a debt-to-equity ratio of 2.07, a quick ratio of 2.27 and a current ratio of 3.16. Jazz Pharmaceuticals has a 52-week low of $125.36 and a 52-week high of $169.98.
In related news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $150.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 372,028 shares of the company’s stock, valued at approximately $55,804,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Jazz Pharmaceuticals news, SVP Finbar Larkin sold 197 shares of the firm’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $149.33, for a total value of $29,418.01. Following the completion of the sale, the senior vice president now directly owns 19,409 shares of the company’s stock, valued at $2,898,345.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $150.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 372,028 shares of the company’s stock, valued at $55,804,200. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,258 shares of company stock worth $2,817,148. Company insiders own 4.40% of the company’s stock.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE boosted its position in Jazz Pharmaceuticals by 13.3% during the first quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 322 shares during the period. Private Advisor Group LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $547,000. Aviva PLC increased its stake in shares of Jazz Pharmaceuticals by 87.1% during the first quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock valued at $6,228,000 after purchasing an additional 18,628 shares in the last quarter. Allianz Asset Management GmbH raised its stake in Jazz Pharmaceuticals by 118.2% during the first quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after buying an additional 6,571 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Jazz Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock worth $872,164,000 after purchasing an additional 57,949 shares in the last quarter. 89.79% of the stock is owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.